137 related articles for article (PubMed ID: 27286673)
1. [Uveal and iridociliary melanomas in young patients : A retrospective analysis of 57 cases].
Heyer LJ; Metz C; Flühs D; Heyer CM; Bornfeld N
Ophthalmologe; 2016 Dec; 113(12):1046-1050. PubMed ID: 27286673
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
3. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.
Petrovic A; Bergin C; Schalenbourg A; Goitein G; Zografos L
Ophthalmology; 2014 Apr; 121(4):898-904. PubMed ID: 24405742
[TBL] [Abstract][Full Text] [Related]
4. [Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].
Gambrelle J; Kodjikian L; Rouberol F; Donate D; Duquesne N; Jean-Louis B; Chauvel P; Gérard JP; Romestaing P; Grange JD
J Fr Ophtalmol; 2004 Jan; 27(1):40-7. PubMed ID: 14968076
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
6. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
Marinkovic M; Horeweg N; Laman MS; Bleeker JC; Ketelaars M; Peters FP; Luyten GPM; Creutzberg CL
Br J Ophthalmol; 2018 Aug; 102(8):1154-1159. PubMed ID: 29122824
[TBL] [Abstract][Full Text] [Related]
8. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma.
Seibel I; Cordini D; Hager A; Tillner J; Riechardt AI; Heufelder J; Davids AM; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1787-92. PubMed ID: 27376824
[TBL] [Abstract][Full Text] [Related]
9. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
Conway RM; Poothullil AM; Daftari IK; Weinberg V; Chung JE; O'Brien JM
Arch Ophthalmol; 2006 Jun; 124(6):838-43. PubMed ID: 16769837
[TBL] [Abstract][Full Text] [Related]
10. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.
Gragoudas ES; Lane AM; Munzenrider J; Egan KM; Li W
Trans Am Ophthalmol Soc; 2002; 100():43-8; discussion 48-9. PubMed ID: 12545676
[TBL] [Abstract][Full Text] [Related]
11. Survival after proton-beam irradiation of uveal melanomas.
Kodjikian L; Roy P; Rouberol F; Garweg JG; Chauvel P; Manon L; Jean-Louis B; Little RE; Sasco AJ; Grange JD
Am J Ophthalmol; 2004 Jun; 137(6):1002-10. PubMed ID: 15183783
[TBL] [Abstract][Full Text] [Related]
12. Conservative management of suspicious melanocytic lesions of the iris.
Oxenreiter MM; Lane AM; Jain P; Kim IK; Gragoudas ES
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1319-1324. PubMed ID: 30919077
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up after uveal melanoma charged particle therapy.
Char DH; Kroll SM; Castro J
Trans Am Ophthalmol Soc; 1997; 95():171-87; discussion 187-91. PubMed ID: 9440169
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium plaque radiation for iris and iridociliary melanomas: development of dry eyes?
Razzaq L; de Keizer RJ
Br J Ophthalmol; 2010 Nov; 94(11):1549-50. PubMed ID: 20516146
[No Abstract] [Full Text] [Related]
15. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
16. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences.
Caujolle JP; Paoli V; Chamorey E; Maschi C; Baillif S; Herault J; Gastaud P; Hannoun-Levi JM
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1218-24. PubMed ID: 23177670
[TBL] [Abstract][Full Text] [Related]
17. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience.
Caujolle JP; Mammar H; Chamorey E; Pinon F; Herault J; Gastaud P
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):98-103. PubMed ID: 19910136
[TBL] [Abstract][Full Text] [Related]
18. Salvage proton beam therapy in local recurrent uveal melanoma.
Riechardt AI; Cordini D; Dobner B; Seibel I; Gundlach E; Rehak M; Hager A; Stark R; Moser L; Joussen AM
Am J Ophthalmol; 2014 Nov; 158(5):948-56. PubMed ID: 25038327
[TBL] [Abstract][Full Text] [Related]
19. High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy.
Finger PT; Reddy S; Chin K
Arch Ophthalmol; 2007 Aug; 125(8):1051-8. PubMed ID: 17698751
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy.
Summanen P; Immonen I; Heikkonen J; Tommila P; Laatikainen L; Tarkkanen A
Ophthalmic Surg; 1993 Feb; 24(2):82-90. PubMed ID: 8446359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
